Across TCGA pan-cancer cohorts, FRG1HP Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FRG1HP data layer compared with 20 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher FRG1HP Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FRG1HP expression acts as an unfavorable survival marker.
READ are the cancer types where FRG1HP Mutation most reproducibly stratifies survival.